Related Experiment Video

Updated: May 30, 2026

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Nuclear drug delivery for cancer chemotherapy

Meihua Sui1, Wenwen Liu, Youqing Shen

  • 1Center for Bionanoengineering and the State Key Laboratory of Chemical Engineering, Department of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310027, China.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|August 18, 2011
PubMed

Insights

Nanosystems enhance chemotherapy by delivering drugs inside cancer cells and to the nucleus. This targeted approach improves treatment effectiveness and reduces side effects for cancer patients.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Research

Background:

  • Small-molecule chemotherapeutics are often DNA-toxins requiring nuclear delivery for efficacy.
  • Intracellular delivery via nanosystems can improve therapeutic outcomes and reduce side effects.
  • Targeting the nucleus is crucial for many anticancer drugs to reach their DNA targets.

Purpose of the Study:

  • To review biological barriers in nuclear drug delivery for cancer chemotherapy.
  • To summarize recent advancements in nuclear drug delivery strategies.
  • To highlight design considerations for effective in vivo nuclear drug delivery vehicles.

Main Methods:

  • Literature review of nanosystem applications in targeted cancer therapy.
  • Analysis of strategies for overcoming biological barriers to nuclear entry.
  • Discussion of challenges and future directions in nuclear drug delivery.

Main Results:

  • Nanosystems offer unique properties for targeted intracellular and nuclear delivery.
  • Overcoming biological barriers is key to successful nuclear drug delivery.
  • Various strategies are being developed to enhance nuclear accumulation of chemotherapeutics.

Conclusions:

  • Nuclear drug delivery is essential for maximizing the efficacy of DNA-targeting chemotherapies.
  • Further research is needed to overcome existing obstacles for clinical translation.
  • Designing effective nanosystems for in vivo nuclear delivery holds significant therapeutic promise.

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...